Featured by leading Southeast Asian technology media e27, EpiSante Biomedical highlights Taiwan's biotechnology innovation and its vision for international growth.
On November 5, 2026, e27, a leading Southeast Asian technology and startup media platform, published a feature article titled "Taiwan's envoy says its startups are capable enough to go global, with Singapore as the first step." The article highlighted Taiwanese startups participating in SWITCH 2026 in Singapore and featured EpiSante Biomedical as an example of Taiwan's innovation in biotechnology and healthcare.
Held from October 27 to 29, 2026, at the Marina Bay Sands Expo & Convention Centre in Singapore, SWITCH 2026 brought together 33 Taiwanese startups under the Startup Island TAIWAN initiative. The participating companies engaged with international investors, corporations, and potential business partners, demonstrating Taiwan's growing momentum in global innovation and entrepreneurship.
In the report, Dr. Chen-Yuan Tung, Representative of the Taipei Representative Office in Singapore, highlighted the innovation capabilities of Taiwanese startups across artificial intelligence, energy, climate technology, and healthcare. He also emphasized Singapore's role as an important starting point for Taiwanese startups seeking international partnerships and global market opportunities.
Advancing DNA Methylation Technologies for Cancer Detection Research
In its coverage of healthcare innovation, e27 highlighted EpiSante Biomedical's technological development in the field of liver cancer-related testing.
Liver cancer remains a significant public health concern in Asia. Exploring innovative approaches to earlier disease identification continues to be an important focus of cancer research and precision medicine.
EpiSante Biomedical focuses on DNA methylation analysis and integrates liquid biopsy technologies to investigate methylation patterns in circulating cell-free DNA (cfDNA) from blood samples. The company aims to explore the potential applications of these molecular biomarkers in liver cancer-related research and cancer detection technologies.
In the report, Lance Lu, Director of Data Science at EpiSante Biomedical, shared the company's progress in developing liver cancer-related testing technologies and its patented technological innovations. This recognition reflects growing international interest in the potential of DNA methylation analysis within molecular diagnostics.
EpiSante Biomedical will continue to strengthen its epigenetic analysis capabilities and advance the development of its molecular testing platforms, while exploring potential applications in early cancer risk assessment and precision medicine.
Singapore as a Strategic Gateway to ASEAN Healthcare Markets
Beyond technological development, EpiSante Biomedical is also actively pursuing international business expansion.
According to the e27 report, the company is planning to establish Singapore as an important base for its international operations, using the city-state as a strategic starting point for exploring business opportunities across ASEAN markets, including Malaysia, Thailand, and Vietnam.
Singapore offers a well-developed ecosystem in finance, logistics, talent, and healthcare, making it an important regional hub for international business and cross-border collaboration.
For biotechnology and healthcare companies seeking to expand internationally, Singapore provides valuable opportunities to establish regional partnerships and connect with the broader Southeast Asian healthcare ecosystem.
EpiSante Biomedical aims to build partnerships with hospitals, clinics, and healthcare institutions across ASEAN, gradually expanding regional collaboration and exploring opportunities for the application of its diagnostic technologies.
From Taiwan's Innovation Ecosystem to Global Opportunities in Precision Health
Being featured by e27 represents an important opportunity to introduce EpiSante Biomedical's technological direction to the international community. It also reflects the growing participation of Taiwan's biotechnology and healthcare industries in the global innovation ecosystem.
EpiSante Biomedical will continue to focus on DNA methylation analysis and liquid biopsy technologies, advancing its molecular diagnostic platforms and exploring applications in cancer detection research, post-treatment monitoring, and precision health management.
The company also looks forward to establishing partnerships with international healthcare institutions, pharmaceutical companies, and biotechnology industry leaders to promote technological exchange and cross-border collaboration.
From Taiwan to the world, with Singapore as a strategic starting point, EpiSante Biomedical is committed to advancing epigenetic innovation and international collaboration, creating new possibilities for cancer research, molecular diagnostics, and precision health management.
International Media Coverage
Media: e27
Publication Date: November 5, 2026
Original Article: Taiwan's envoy says its startups are capable enough to go global, with Singapore as the first step
About EpiSante Biomedical
EpiSante Biomedical is a biotechnology company focused on epigenetic technologies and precision medicine. With DNA methylation analysis and liquid biopsy as its core areas of technological development, the company is dedicated to exploring non-invasive molecular testing applications in cancer detection, disease monitoring, and precision health management.
Through continued research and technological innovation, EpiSante Biomedical aims to advance molecular diagnostic technologies and expand international collaborations, contributing to the future development of cancer research and personalized healthcare.